
|Videos|July 14, 2015
Potential Change in Guidelines for Ticagrelor Therapy
Advertisement
Episodes in this series

The results of the PEGASUS-TIMI 54 trial could potentially lead to a change in clinical guidelines to extend the currently recommended 12 months of ticagrelor therapy.
This change would be contingent on patients’ ability to tolerate ticagrelor therapy beyond 12 months and through 33 months, which was the average follow-up in the PEGASUS-TIMI 54 trial.
Comparing the PEGASUS-TIMI 54 trial with the DAPT study, Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, a clinical specialist of cardiovascular medicine at Saint Barnabas Medical Center, notes the population in the former study included a more real-to-life population of higher-risk patients.
Advertisement
Related to this article

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Balanced exposure to clinical and nonclinical careers, timed to each pathway's application calendar and built into each curriculum's structure, can help pharmacy students choose their next step deliberately.

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.

Adrabetadex cut the risk of death by 55%, but its boxed warning for permanent hearing loss means patients need regular hearing tests.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
2
Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C
3
When Medicine Changes Faster Than Health Care: Preparing for a New Era
4
US Loses Measles Elimination Status After 26 Years
5








